Kyungsun Han1, Jinghwa Wang1, Jae-Gu Seo2, Hojun Kim3. 1. Department of Rehabilitation Medicine of Korean Medicine, Dongguk University Ilsan Hospital, 814 Siksa-dong, Goyang, Gyeonggi-do, Republic of Korea. 2. R&D Center, Cell Biotech Co. Ltd., Gimpo, 415-871, Republic of Korea. 3. Department of Rehabilitation Medicine of Korean Medicine, Dongguk University Ilsan Hospital, 814 Siksa-dong, Goyang, Gyeonggi-do, Republic of Korea. kimklar@dongguk.ac.kr.
Abstract
BACKGROUND: The purpose of this study was to elucidate the effects of a dual-coated probiotic supplement (Duolac Care) on symptoms of diarrhea-predominant irritable bowel syndrome in a randomized double-blind clinical trial. METHODS:Fifty subjects with diarrhea-predominant irritable bowel syndrome were randomly assigned to either the non-coating group or the dual-coating group in order to receive two capsules per day of multi-species probiotics containing 5 billion bacteria per capsule for 4 weeks. Data from an adequate relief questionnaire were used in assessment of primary outcome. Daily records of stool frequencies and the Bristol stool scale, a weekly symptom diary using 100-mm visual analog scale, and Beck depression inventories were collected. Blood tests including blood cell counts, interleukin-10, tumor necrosis factor-alpha and inducible nitric oxide synthase, and regulatory T cells-CD4 + CD25high T cells, CD4 + LAP + T cells and CD25high + LAP + T cells-were analyzed before and after the study. The shift of gut microbiota was investigated using a quantitative real-time polymerase chain reaction assay. RESULTS: Responses to the adequate relief questionnaire indicated significant improvement in overall discomfort in the dual-coating group and the ratio of normal stools to hard or watery stools had a better effect from dual-coated probiotics compared to non-coated probiotics. This may be due to a shift of intestinal microbiota, as our correlation analysis showed significant negative correlation between Bifidobacterium and urgency of defecation. CONCLUSIONS: Our result implies that dual-coating layers of probiotic supplement can be a candidate for treatment of diarrhea-predominant irritable bowel syndrome.
RCT Entities:
BACKGROUND: The purpose of this study was to elucidate the effects of a dual-coated probiotic supplement (Duolac Care) on symptoms of diarrhea-predominant irritable bowel syndrome in a randomized double-blind clinical trial. METHODS: Fifty subjects with diarrhea-predominant irritable bowel syndrome were randomly assigned to either the non-coating group or the dual-coating group in order to receive two capsules per day of multi-species probiotics containing 5 billion bacteria per capsule for 4 weeks. Data from an adequate relief questionnaire were used in assessment of primary outcome. Daily records of stool frequencies and the Bristol stool scale, a weekly symptom diary using 100-mm visual analog scale, and Beck depression inventories were collected. Blood tests including blood cell counts, interleukin-10, tumor necrosis factor-alpha and inducible nitric oxide synthase, and regulatory T cells-CD4 + CD25high T cells, CD4 + LAP + T cells and CD25high + LAP + T cells-were analyzed before and after the study. The shift of gut microbiota was investigated using a quantitative real-time polymerase chain reaction assay. RESULTS: Responses to the adequate relief questionnaire indicated significant improvement in overall discomfort in the dual-coating group and the ratio of normal stools to hard or watery stools had a better effect from dual-coated probiotics compared to non-coated probiotics. This may be due to a shift of intestinal microbiota, as our correlation analysis showed significant negative correlation between Bifidobacterium and urgency of defecation. CONCLUSIONS: Our result implies that dual-coating layers of probiotic supplement can be a candidate for treatment of diarrhea-predominant irritable bowel syndrome.
Authors: Jung-hyun Rho; Damian P Wright; David L Christie; Keith Clinch; Richard H Furneaux; Anthony M Roberton Journal: J Bacteriol Date: 2005-03 Impact factor: 3.490
Authors: K Madsen; A Cornish; P Soper; C McKaigney; H Jijon; C Yachimec; J Doyle; L Jewell; C De Simone Journal: Gastroenterology Date: 2001-09 Impact factor: 22.682
Authors: H J Kim; M Camilleri; S McKinzie; M B Lempke; D D Burton; G M Thomforde; A R Zinsmeister Journal: Aliment Pharmacol Ther Date: 2003-04-01 Impact factor: 8.171